Tumor cells may develop resistance to ferroptosis-dependent cancer treatment by augmenting GPX4 expression, and GPX4-targeted attenuation of its activity has been proposed as a potential approach to sensitize HCC to the treatment of Sora 29. This evidence concerns the gene GPX4 and cancer.